Perspective of the market prospects of antiviral drugs – antiviral drugs, the ma
Reports in various media nowadays, you can see from time to time with the bird flu related news. Because people with high demand for flu drug, Roche's antiviral Tamiflu production sales climbing higher and higher. However, despite the actions of global reserves of Tamiflu sales of the drug has the potential to break through two billion U.S. dollars, but also unwilling to people of other antiviral drugs, we began to cut a striking figure in the market. Large domestic pharmaceutical companies in particular – the transfer of Roche Pharmaceutical Group received "domestic version of" successful listing of Tamiflu, the influenza drug market in China will bring about remarkable changes in the structure.
Company, according to market research firm Datamonitor's study indicates that in the long run, treatment of respiratory syncytial virus (RSV) of antiviral drugs and vaccines may gradually focus the treatment to existing treatments in the field of challenging . The focus therapeutic areas, including herpes simplex virus / varicella zoster virus (HSV / VZVs) and cytomegalovirus (CMVs).
Three companies dominate Long time, the treatment of herpes and respiratory antiviral market has been by the European pharmaceutical company GlaxoSmithKline, Roche and Novartis control. In 2004, the three company's total sales accounted for the market share of 86%. However, three relatively limited competition between the companies, including GlaxoSmithKline in the HSV / VZV dominant therapeutic areas, Roche CMV treatment in the market dominating position. Novartis Although HSV / VZV therapeutic areas lighter weight, but it is likely through the introduction of drugs A-60444 in the RSV antiviral market leading position. A-60444 is being developed by Novartis and the United Kingdom Arrow biotechnology companies to develop small molecule inhibitors of the virus.
In the treatment of infectious diseases (ID), and respiratory diseases, herpes antiviral market, GlaxoSmithKline are leading. In 1981, GlaxoSmithKline launched ganciclovir (Zovirax / Shu Wei therapy), the HSV / VZV treatment on the market first established his position. However, as Shu Wei treatment in the last century to lose patent protection of 90 years, the company also suffered a big blow, because at that time, Shu Wei treatment are blockbuster drugs has become one of GSK earnings important source. However, GlaxoSmithKline has launched the 1995 follow-up of drug valaciclovir (Valtrex / Wei Desi). After listing the drug quickly became the market leader, which partly offset the patent invalid because Shu Wei treatment caused the loss. In 2004, Wei Desi rose to blockbuster drugs, with sales of 10 billion U.S. dollars. In the treatment of herpes and respiratory antiviral market, the disease, which accounts for 50% of the share.
Order to establish and maintain their CMV treatment in the market leading position, Roche in the product lifecycle management has also taken effective approach. Roche began to enter this market is in its acquisition of Syntex Pharmaceuticals, the company launched in 1994, then CMV antiviral ganciclovir treatment (Cytovene / Race Meadville). As with GlaxoSmithKline, Roche in the drug in 2002 and 2005 in succession to lose patent protection between the occasion of the launch of the follow-up product valganciclovir (Valcyte / million Zevi), to deal with generic competition, to prevent the Pharmaceutical sales fell for.
I am an expert from chinaslurrypump.com, while we provides the quality product, such as Sump Pump EVM , slurry pump impeller, slurry pump suppliers,and more.
Processing your request, Please wait....
